Bristol-Myers Squibb Company and Pfizer Inc. announced that 12 Eliquis abstracts will be presented at the AHA Scientific Sessions 2016, to be held November 12-16 in New Orleans. Among these abstracts, the Bristol Myers-Squibb and Pfizer Alliance will present final data from the randomized AEGEAN (Assessment of an Educational and Guidance Program for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study, highlighting adherence and persistence data for nonvalvular atrial fibrillation (NVAF) patients treated with Eliquis to reduce the risk of stroke.
These data are based on an evaluation of an additional education program versus standard of care patient education. Additional post-hoc analyses from the pivotal ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) study and retrospective real-world data analyses from ACROPOLIS (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies) will also be presented.
“We are proud to build on the growing body of clinical and real-world evidence for the use of Eliquis,” said Rory O’Connor, M.D., Chief Medical Officer, Internal Medicine, Pfizer Innovative Health. “At this year’s AHA Scientific Sessions, we’ll also share data on patient adherence to anticoagulant therapy, which is critical for the reduction of stroke risk in patients with nonvalvular atrial fibrillation.”
“As part of our steadfast commitment to the ongoing evaluation of Eliquis, we continue to gather insights from real-world practice to complement the results we’ve seen in randomized clinical trials,” said Christoph Koenen, M.D., MBA, VP, Development Lead, Eliquis, Bristol-Myers Squibb. “These analyses form part of our ACROPOLIS global real-world data program, which evaluates data from regions around the world collected through medical records, insurance claims databases and national health data systems to further inform healthcare decision-making.”
